Locations:
Search IconSearch

Blood Cancers

Cancer patient being hugged by a loved one
September 4, 2024/Cancer/Blood Cancers

Study Finds Immunotherapy Increases Three-Year Survival in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone

Dr. Mukherjee at Cleveland Clinic
April 1, 2024/Cancer/Blood Cancers

Many Patients with “Indolent” Systemic Mastocytosis Experience Rapid Decline and Lower Survival

First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers

Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers

Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Treating older patients with diffuse large B-cell lymphoma (DLBCL)
January 18, 2024/Cancer/Blood Cancers

Trial for Patients 75 and Older with Diffuse Large B-Cell Lymphoma Helps Address Care Inequities

Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients

23-CNR-4221120 ASH 2023 Graphics-CQD
December 4, 2023/Cancer/Blood Cancers

Ten ASH Presentations You Don’t Want to Miss

Cleveland Clinic oncologists’ selected abstracts

CAR T-cell therapy
April 5, 2023/Cancer/Blood Cancers

Insights About CAR T-Cell Therapy

Dispelling myths and sharing practical experiences

CAR T-cell therapy for multiple myeloma
March 13, 2023/Cancer/Blood Cancers

Ide-CEL CAR T-Cell Therapy Effective in Multiple Myeloma Among Patients with Comorbidities

Research indicates strong rationale for expanding trial eligibility criteria

22-CNR-3245747-CQD-Hero-650×450 aplastic anemia
September 13, 2022/Cancer/Blood Cancers

Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Retrospective study yields clues to understanding risk of secondary myeloid neoplasms

BackPage 1 of 7Next

Advertisement

Ad